‘Why Biology Is Not Destiny’: An Exchange
By Kathryn Paige Harden et al.,
The New York Review
| 05. 25. 2022
Kathryn Paige Harden, Nick Patterson, Victor I. Reus, and Henry D. Schlinger Jr., reply by M.W. Feldman and Jessica Riskin
In response to:
Why Biology Is Not Destiny from the April 21, 2022 issue
To the Editors:
Marcus Feldman and Jessica Riskin did not like my book. Or rather, they did not like a book called The Genetic Lottery by an author named “Kathryn Paige Harden,” but their review [NYR, April 21] so badly distorts my arguments that I have the curious impression that Feldman and Riskin somehow got their hands on another book entirely, an evil doppelgänger to mine. Therapists, parents, and the unhappily married would recognize the feeling I had upon reading their review the first time: it’s both vexing and bewildering when someone is spoiling for a fight about something you never said.
As a longtime reader of The New York Review of Books, I am surprised and disappointed that this review was published in such an esteemed outlet. Yes, “we all enjoy an intemperate paragraph of syntactically inspired bile,” to quote Zadie Smith, and Feldman and Riskin do deliver the bile. But I assume that, besides wanting to be entertained by vitriol...
Related Articles
By Katie Hunt, CNN | 07.30.2025
Scientists are exploring ways to mimic the origins of human life without two fundamental components: sperm and egg.
They are coaxing clusters of stem cells – programmable cells that can transform into many different specialized cell types – to form...
By Ewen Callaway, Nature | 08.04.2025
For months, researchers in a laboratory in Dallas, Texas, worked in secrecy, culturing grey-wolf blood cells and altering the DNA within. The scientists then plucked nuclei from these gene-edited cells and injected them into egg cells from a domestic dog ...
By Kristel Tjandra, Genetic Engineering & Biotechnology News | 07.30.2025
CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on various fronts. But getting CRISPR experiments right in the lab isn’t simple...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...